Furthermore, the use of genomic aberrations as prognostic and predictive biomarkers is already standard clinical practice in BC, particularly the use of HER2 amplification status for both prognosis and to predict response to anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast cancer.